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Background/Aims: Data on the comparative effectiveness of infliximab (IFX) or adalimumab 
(ADA) in patients with Crohn’s disease (CD) are rare, particularly for Asian patients. We com-
pared the key clinical outcomes (surgery, hospitalization, and corticosteroid use) of use of these 
two drugs in biologic-naive Korean patients with CD. 
Methods: Using National Health Insurance claims, we collected data on patients who were diag-
nosed with CD and exposed to IFX or ADA between 2010 and 2016. 
Results: We included 1,488 new users of biologics (1,000 IFX users and 488 ADA users). Over 
a median follow-up period of 2.1 years after starting biological therapy, no significant differences 
were found between IFX and ADA users in the risks for surgery (ADA vs IFX: adjusted hazard 
ratio [aHR], 1.22; 95% confidence interval [CI], 0.81 to 1.84), hospitalization (aHR, 1.02; 95% 
CI, 0.81 to 1.28), and corticosteroid use (aHR, 0.82; 95% CI, 0.56 to 1.19). These results were 
unchanged even when only patients who used biologics for over 6 months were analyzed (aHR 
[95% CI]: surgery, 1.31 [0.82 to 2.11]; hospitalization, 1.02 [0.80 to 1.30]; corticosteroid use, 0.80 
[0.54 to 1.18]). Additionally, these results were unchanged in patients treated with biologics as 
monotherapy or in combination with immunomodulators. 
Conclusions: In this nationwide population-based study, no significant difference was found 
in the long-term effectiveness of IFX and ADA in the real-world setting of biologic-naive Korean 
patients with CD. In the absence of trials to directly compare IFX and ADA, our study indicates 
that the selection of one of these two biologics can be determined by patient and/or physician 
preference. (Gut Liver 2021;15:92-99)
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INTRODUCTION
Crohn’s disease (CD) is a longstanding and relapsing 
inflammatory disease that can affect the entire gastroin-
testinal tract, often requiring life-long medical treatment.1 
Biological tumor necrosis factor α (TNF-α) inhibitors such 
as adalimumab (ADA) and infliximab (IFX) is one of the 
most effective drugs, leading to the induction and main-
tenance of clinical remission in patients with moderate 
to severe CD.2 In addition, some studies have shown that 
TNF-α inhibitors have improved the prognoses of patients 
with CD by preventing structural damage progression, 
thereby reducing intestinal complications and the need 
for hospitalization and surgery.2 While novel biologics and 
small molecule drugs are rapidly evolving—with different 
mechanisms of action from TNF-α inhibitors—TNF-α 
inhibitors are still considered a milestone in the treatment 
of CD.2,3
Two TNF-α inhibitors—ADA and IFX—were approved 
for the treatment of CD in South Korea since 2005 and 
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2010, respectively. The main differences between these two 
drugs are the route of administration (intravenous vs sub-
cutaneous) and the interval between doses (2 months vs 2 
weeks). Although ADA and IFX were proven in random-
ized clinical trials (RCTs) to be effective in the treatment 
of CD compared to placebo,4,5 there have been no head-
to-head comparison trials. Thus, there has been an unmet 
need among physicians and patients to better understand 
the relative efficacy of ADA and IFX. 
Some network meta-analyses have demonstrated no 
difference in the rates of induction and maintenance of 
clinical remission between ADA and IFX.6,7 In addition, 
another network meta-analysis showed no difference in the 
rates of hospitalization and surgery of CD between ADA 
and IFX.8 However, indirect comparison through network 
meta-analysis studies in the absence of head-to-head com-
parison trials may not be able to detect small differences 
between ADA and IFX that do exist (type II error may oc-
cur). Moreover, very few trials were included in previous 
network meta-analyses that assessed short-term clinical 
outcomes within 54 weeks and had restricted inclusion cri-
teria.
Unfortunately, only a few observational studies have 
compared key clinical outcomes such as surgery and hos-
pitalization between patients with CD who received ADA 
and IFX therapy.9-13 Furthermore, the results were incon-
sistent, and most prior studies on this topic have been con-
ducted only in Western countries.9-13 Despite an increase in 
the incidence of CD in Asia,14,15 comparative studies of the 
efficacy of ADA and IFX in Asian patients are extremely 
scarce. Therefore, we compared the effectiveness of ADA 
and IFX in biologic-naive patients with CD, using a na-
tionwide population-based study based on South Korean 
health insurance claims database. To better assess the real-
world outcomes of these two TNF-α inhibitors, we com-
pared abdominal surgery, hospitalizations, and the need 
for corticosteroids.
MATERIALS AND METHODS
1. Data source 
The South Korean government operates National 
Health Insurance program. This is a mandatory nationwide 
insurance program. Medical institutions submit health 
care utilization information electronically for reimburse-
ment purposes, and this information is integrated into the 
Health Insurance Review Agency (HIRA) claims database. 
The HIRA database contains a wide range of information 
including principal diagnosis, demographic characteristics, 
ambulatory care history, procedures, and prescriptions da-
tabase and covers the entire population of South Korea.16-18 
This study was conducted using HIRA database between 
2008 and 2016.
2. Patient identification and data capture
To improve the diagnostic accuracy of CD, we consid-
ered both the appropriate diagnostic codes and CD-related 
drug prescriptions.16-18 The definition of CD has been 
described in the previous studies.16-18 We used a washout 
period of 2 years because previous prevalent cases might 
confound the incidence rate. Accordingly, we were able 
to analyze patients who were diagnosed with CD and re-
ceived biological therapy between January 1, 2010, and De-
cember 31, 2016. Patients who were exposed to both ADA 
and IFX and patients with a history of abdominal surgery 
before starting biological therapy were excluded. 
The primary outcomes of our study were abdominal 
surgery, hospitalizations, and the need for corticosteroids. 
Abdominal surgery was identified by using the procedural 
code for major surgery. Appendectomy (Q2861, Q2862, 
and Q2863) was not included in the definition of abdomi-
nal surgery. Hospitalizations were defined as cases where 
the patient was admitted to the department of gastroen-
terology for 3 days or more. New corticosteroid use was 
defined as moderate- or high-dose corticosteroid use (≥200 
mg hydrocortisone, ≥50 mg methylprednisolone, or ≥30 
mg prednisolone) two months after the first biologics pre-
scription.
We considered surgical history of perianal diseases. Sur-
gical history of perianal diseases was defined as the pres-
ence of surgical procedure codes for anal fissure (Q2950), 
anal fistula (Q2974, Q2975, Q2976 Q2977, Q2978, and 
Q2979), and periproctal abscess (Q2881, Q2882, and 
Q2883) before starting biological therapy.
3. Statistical analysis
For each IFX and ADA user group, the crude risk of 
outcomes was described by log-rank tests and the Kaplan-
Meier method. In Cox proportional hazards models, 
potential confounding variables were adjusted. Gender, 
the period from CD diagnosis to first biologics use, age, re-
gion, hospital scale, steroids use at the time of first biolog-
ics use, and surgical history of perianal diseases were ad-
justed as time-fixed covariates. Concomitant medications 
(immunomodulators and 5-aminosalicylic acid) and the 
use period of cumulative biologics were adjusted as time-
dependent covariates. 
We conducted a sensitivity analysis on patients who 
used biologics for over 6 months. We also conducted a 
stratified analysis based on the use of TNF-α inhibitors 
monotherapy or combination therapy (concomitant use of 
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immunomodulators). TNF-α inhibitors-based combina-
tion therapy was defined as prescriptions of immunomod-
ulators within 30 days before and/or after the biologics 
start date.12,13 p-values<0.05 were considered statistically 
significant. All analyses were performed using the SAS En-
terprise Guide (SAS Institute, Inc., Cary, NC, USA).
4. Ethical considerations
This study protocol was approved by the Institutional 
Review Board (IRB) of Severance Hospital, Yonsei Univer-
sity College of Medicine (IRB number: 4-2017-0927). This 
study is a retrospective study using medical record review 
and so informed consent was waived.
RESULTS
1. Patient characteristics
A total of 8,974 patients diagnosed with CD were iden-
tified. Of these patients, 1,838 started their first TNF-α 
inhibitors during the study period. Of these 1,838 patients, 
153 were excluded due to overlapping IFX and ADA use, 
and 197 were excluded due to abdominal surgery before 
the start of TNF-α inhibitors. Ultimately, 1,488 patients 
were included in the study. Of these 1,488 patients, 1,000 
were treated with IFX and 488 were treated with ADA as 
their first TNF-α inhibitors. The median follow-up period 
was 2.1 years (interquartile range, 1.0 to 3.5 years).
The demographic characteristics of the study popula-
tion are shown in Table 1. The mean period from CD di-
agnosis to first biologics use in IFX users was shorter than 
in ADA users (1.4±1.5 years vs 1.7±1.5 years, p<0.001), 
whereas the mean period of biologics use in IFX users was 
longer than in ADA users (2.3±1.7 years vs 1.8±1.3 years, 
p<0.001). The rate of steroid use in IFX users was higher 
than in ADA users (28.3% vs 13.9%, p<0.001), while the 
rate of concomitant immunomodulators use was not 
different between IFX and ADA users (73.4% vs 76.8%, 
p=0.171). Surgical history of perianal diseases before bio-
logics use in IFX users was higher than in ADA users (6.4% 
vs 2.3%, p<0.001). 
2. Comparative effectiveness of ADA versus IFX
There were no significant differences in the cumulative 
rates of abdominal surgery (p=0.089) (Fig. 1A), hospitaliza-
tion (p=0.209) (Fig. 1B), and corticosteroid use (p=0.450) 
(Fig. 1C) between IFX and ADA users. At 1 year, 3 years, 
and 5 years after the first biologics start, the cumulative 
rates of surgery were 4.6%, 8.0%, and 11.8%, respectively, 
for IFX users, and 6.3%, 9.6%, and 12.2%, respectively, for 
ADA users. The cumulative rates of hospitalization were 
17.9%, 30.1%, and 36.2%, respectively, for IFX users, and 
Table 1. Baseline Characteristics of the Study Population
Characteristics Infliximab users (n=1,000) Adalimumab users (n=488) p-value
Male sex 694 (69.4) 357 (73.2) 0.152
Age at diagnosis of CD, yr 25.0±11.4 25.4±10.8 0.449
Age at first biologics use, yr 26.4±11.4 27.2±10.9 0.175
The period from CD diagnosis to first biologics use, yr 1.4±1.5 1.7±1.5 <0.001
The period of biologics use, yr 2.3±1.7 1.8±1.3 <0.001
   Less than 6 mo 166 (16.6) 75 (15.4) 0.596
   More than 6 mo 834 (83.4) 413 (84.6)
Region at first biologics use
   Seoul 454 (45.4) 223 (45.7) 0.958
   Outside Seoul 546 (54.6) 265 (54.3)
Hospital scale at first biologics use
   Tertiary hospitals 718 (71.8) 355 (72.8) 0.749
   General hospitals/community hospitals/clinics 282 (28.2) 133 (27.2)
Medication use at first biologics use
   5-ASAs 571 (57.1) 292 (59.8) 0.343
   Steroids 283 (28.3) 68 (13.9) <0.001
   Immunomodulators 545 (54.5) 281 (57.6) 0.286
Concomitant immunomodulators (±30 day)
   No 266 (26.6) 113 (23.2) 0.171
   Yes 734 (73.4) 375 (76.8)
Surgical history of perianal diseases before biologics use* 64 (6.4) 11 (2.3) <0.001
Data are presented as number (%) or mean±SD.
CD, Crohn’s disease; 5-ASA, 5-aminosalicylic acid.
*Surgical history of perianal diseases was defined as the presence of surgical procedure codes for anal fissure (Q2950), anal fistula (Q2974, Q2975, 
Q2976, Q2977, Q2978, and Q2979), and perirectal abscess before biologic use (Q2881, Q2882, and Q2883). 
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16.6%, 31.5%, and 46.2%, respectively, for ADA users. For 
corticosteroid use, the cumulative rates at 1, 3 and 5 years 
were 5.3%, 13.2%, and 18.1%, respectively, for IFX users, 
and 5.2%, 10.6%, and 20.8%, respectively, for ADA users.
Even after adjusting for confounding variables, there 
were no significant differences in the risk of surgery (ad-
justed hazard ratio [aHR], 1.22; 95% confidence interval 
[CI], 0.81 to 1.84), hospitalizations (aHR, 1.02; 95% CI, 
0.81 to 1.28), and corticosteroid use (aHR, 0.82; 95% CI, 
0.56 to 1.19) between the two groups (Table 2). 
3. Sensitivity analysis and stratified analysis
In sensitivity analysis of patients who used biologics for 
over 6 months, we also observed no significant differences 
in the risk of surgery (aHR, 1.31; 95% CI, 0.82 to 2.11), 


























































































































































































Fig. 1. Survival rates without (A) abdominal surgery, (B) hospitalization, and (C) new corticosteroid use.
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ticosteroid use (aHR, 0.80; 95% CI, 0.54 to 1.18) between 
IFX and ADA users (Table 2). In addition, there were no 
significant differences for the three outcomes between 
ADA and IFX users with either TNF-α inhibitors mono-
therapy or combination therapy (Table 3).
DISCUSSION
In this study of 1,488 biologic-naive Korean CD pa-
tients, we observed that IFX and ADA were comparable in 
terms of risk of major abdominal surgery, CD-related hos-
pitalization, and new initiation of corticosteroids. These re-
sults were unchanged even when analyzed for patients who 
used biologics for over 6 months. In addition, these results 
were the same for patients treated with biological mono-
therapy or combination therapy. Our findings demonstrate 
that IFX and ADA are comparable in their real-world CD-
related outcomes. 
Surgery and hospitalization signal severe disease and are 
an important cause of morbidity in patients with CD.19 Up 
to two-thirds of patients with CD require at least one CD-
Table 2. Comparative Effectiveness of Adalimumab versus Infliximab in Biologic-Naive Patients with CD
Outcomes













   Abdominal surgery 37 4.9 (3.5–6.6) 72 4.2 (3.3–5.2) 1.22 (0.81–1.84) 0.345
   CD-related hospitalization 115  15.2 (12.6–18.2) 255 14.8 (13.1–16.7) 1.02 (0.81–1.28) 0.889
   New steroid use (after 2 mo) 39 5.2 (3.7–7.0) 111 6.5 (5.3–7.7) 0.82 (0.56–1.19) 0.296
Biologics users over 6 months
   Abdominal surgery 29 4.1 (2.8–5.8) 51 3.2 (2.4–4.2) 1.31 (0.82–2.11) 0.259
   CD-related hospitalization 101 14.3 (11.7–17.2) 224 14.1 (12.4–16.1) 1.02 (0.80–1.30) 0.855
   New steroid use (after 2 mo) 36 5.1 (3.6–6.9) 104 6.6 (5.4–7.9) 0.80 (0.54–1.18) 0.265
CD, Crohn’s disease; py, person-years; CI, confidence interval; HR, hazard ratio.
*Adjusted for sex, age at first biologic use, time from CD diagnosis to first biologic use, region, hospital scale, and medication use (5-aminosalicylic 
acid, immunomodulators, and steroids) at first biologic use, cumulative duration of biologic use, and surgical history of perianal diseases.
Table 3. Comparative Effectiveness of Adalimumab versus Infliximab in Biologic-Naive Patients with CD Stratified by the Use of TNF-α Inhibitors 
as Monotherapy and in Combination with Immunomodulatory Therapy
Outcomes












TNF-α inhibitors monotherapy (n=379)
   Overall biologics users
      Abdominal surgery 13 7.1 (3.9–11.7)   24 5.2 (3.4–7.5) 1.39 (0.68–2.85) 0.364
      CD-related hospitalization 30 16.4 (11.2–22.9)   69 14.9 (11.6–18.7) 1.17 (0.75–1.84) 0.488
      New steroid use (after 2 mo) 13 7.1 (3.5–11.0)   37 8.0 (5.7–10.8) 0.98 (0.51–1.87) 0.938
   Biologics users over 6 mo  
      Abdominal surgery 12 7.0 (3.7–11.7)   16 3.9 (2.3–6.1) 2.05 (0.92–4.57) 0.079
      CD-related hospitalization 25 14.5 (9.6–21.0)   58 14.0 (10.7–17.9) 1.13 (0.69–1.85) 0.621
      New steroid use (after 2 mo) 13 7.6 (4.2–12.4)   33 8.0 (5.5–11.0) 1.05 (0.54–2.03) 0.894
TNF-α inhibitors+immunomodulatory therapy (n=1,109)
   Overall biologics users
      Abdominal surgery 24 4.2 (2.7–6.1)   48 3.8 (2.8–5.0) 1.17 (0.71–1.94) 0.542
      CD-related hospitalization 85 14.9 (11.9–18.2) 186 14.8 (12.8–17.1) 0.98 (0.75–1.28) 0.871
      New steroid use (after 2 mo) 26 4.5 (3.0–6.5)   74 5.9 (4.7–7.3) 0.82 (0.52–1.30) 0.395
   Biologics users over 6 mo
      Abdominal surgery 17 3.2 (1.9–4.9)   35 3.0 (2.1–4.1) 1.07 (0.59–1.96) 0.818
      CD-related hospitalization 76 14.2 (11.2–17.6) 166 14.2 (12.1–16.4) 1.00 (0.75–1.32) 0.970
      New steroid use (after 2 mo) 23 4.3 (2.8–6.3)   71 6.1 (4.8–7.6) 0.77 (0.47–1.24) 0.279
CD, Crohn’s disease; TNF, tumor necrosis factor; py, person-years; CI, confidence interval; HR, hazard ratio.
*Adjusted for sex, age at first biologic use, time from CD diagnosis to first biologic use, region, hospital scale, and medication use (5-aminosalicylic 
acid, immunomodulators, and steroids) at first biologic use, cumulative duration of biologic use, and surgical history of perianal diseases.
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related surgery or medical hospitalization.19-21 In addition, 
a significant portion of CD-related costs are attributable to 
medical or surgical hospitalization.22 While several RCTs 
have shown the efficacy of IFX and ADA in achieving in-
duction and maintenance of clinical remission compared 
to placebo, the data on the effect of such therapies on 
modification of natural history, such as reduction in sur-
gery and hospitalization, is scarce. Accordingly, prior net-
work meta-analyses examining comparative effectiveness 
among biologics have focused on clinical response and 
remission. Network meta-analyses by Stidham et al.7 and 
Hazlewood et al.6 have shown no difference between IFX 
and ADA in influencing the induction and maintenance 
of clinical remission in CD. However, the network analysis 
by Singh et al.23 ranked IFX as the most efficacious agent 
for induction and ADA for maintenance of remission. Re-
cently, a network meta-analysis by Mao et al.8 focused on 
the comparative efficacy of biologics for reducing surgery 
and hospitalization. The study revealed that TNF-α inhibi-
tors significantly reduced surgery and hospitalization com-
pared to placebo, with no significant differences between 
IFX and ADA.8 However, RCTs included in this network 
meta-analysis study were extremely few in number (2 IFX 
studies and 1 ADA study). Moreover, these results were 
based on indirect comparisons. 
To our knowledge, this is the first nationwide popu-
lation-based study to compare the long-term outcomes 
of ADA and IFX in Korean CD patients. To date, several 
observational studies have conducted head-to-head com-
parisons of ADA and IFX in CD patients. However, the 
majority of these studies have been conducted in West-
ern countries, and studies on this topic in Asian patients 
have been rarely conducted. Several Western studies have 
shown no difference in clinical response and remission 
between these two TNF-α inhibitors.24-27 Similar to our 
results, some studies from Western countries have shown 
no difference in the risk of surgery, hospitalization, and 
steroid utilization between IFX and ADA.9-11,13,26,28 A retro-
spective cohort study using U.S. Medicare data showed no 
significant difference in the risks of abdominal surgery and 
hospitalization between IFX- and ADA-treated patients 
with CD (n=1,459 and n=871, respectively).10 A U.S. study 
revealed no difference in surgery, hospitalizations or pred-
nisone use within 1 year after initiation of ADA (n=309) or 
IFX (n=723) for CD.11 In another U.S. study using a large 
healthcare database, emergency room visits and hospital-
izations within 6 months of TNF-α inhibitors initiation 
were not statistically different between IFX and ADA us-
ers, although healthcare costs were significantly lower in 
ADA users (n=623) compared with IFX users (n=623).28 
A Canadian study also demonstrated that the rates of sur-
gery, hospitalizations or need for steroids after 12 weeks of 
therapy were similar between ADA users (n=77) and IFX 
users (n=143).26 In addition, a recent study based on health 
administrative databases from Italy reported that the risks 
of steroid utilization, abdominal surgery, and hospitaliza-
tion for infection were not different between ADA and 
IFX new users with CD (n=367 and n=505, respectively).9 
Similarly, in a Danish nationwide population-based cohort 
study of 827 biologic-naive patients, there were no signifi-
cant differences in the rate of CD-related hospitalization, 
major abdominal surgery, and corticosteroid use between 
patients treated with IFX and ADA (n=512 and n=315, 
respectively).13 However, in contrast to our findings, a U.S. 
administrative claims-based study reported a lower risk 
of abdominal surgery, hospitalization, and corticosteroid 
use in patients treated with IFX (n=1,427) compared with 
those treated with ADA (n=1,248).12 
In summary, most of the previous studies as well as our 
study have shown no difference in the clinical efficacy be-
tween IFX and ADA. We conducted a sensitivity analysis 
in order to further compare the long-term effects of IFX 
and ADA in patients who used biologics for 6 months or 
more; this also showed no difference in the outcomes be-
tween the two biologics. In the absence of RCTs comparing 
these two TNF-α inhibitors directly, our findings support 
that the choice of either of ADA or IFX may be left to the 
preference of the patient and/or physician.
This study had several limitations. First, this was a ret-
rospective and observational study, not an interventional 
study; thus, there may be confounding factors that are not 
measured across groups. The potential for confounding 
due to disease severity can be particularly problematic be-
cause administrative data do not include information on 
disease severity such as clinical, biochemical, or endoscop-
ic activity. However, this may not have a significant effect 
on our results, since TNF-α inhibitors are commonly used 
for similar levels of disease activity (moderate to severe 
activity). Furthermore, IFX and ADA were approved only 
for patients with a CD Activity Index of 220 or higher in 
South Korea. In addition, steroid use at the time of the first 
biologics use can reflect the patient’s disease activity, which 
was adjusted in our study. Second, we were also not able to 
assess the effect of dose escalation or interval shortening, 
which are strategies to improve the effectiveness of biolog-
ics. There is no information on the weight of patients in 
the HIRA database. Therefore, it was difficult to accurately 
capture whether the IFX dose was doubled and when it 
was doubled in each of the 1,000 IFX users. In the case of 
ADA, a self-injectable drug, it was also difficult to accu-
rately capture the shortening of interval because the timing 
of prescription and actual administration might have been 
Gut and Liver, Vol. 15, No. 1, January 2021
98  www.gutnliver.org
different. Given these limitations, we were not able to ana-
lyze the data on dose escalation and interval shortening. 
Third, the efficacy of ADA and IFX in remission induction 
and maintenance could not be compared because informa-
tion on disease activity such as the CD Activity Index was 
not available. Fourth, safety outcomes, such as opportunis-
tic or serious infections, were not investigated. Fifth, since 
we were not able to obtain the information from the HIRA 
database before 2008, medical and surgical histories before 
2008 were not analyzed. Lastly, we were unable to assess 
the efficacy of IFX and ADA on perianal diseases because 
claims codes could not distinguish perianal diseases. 
However, we considered surgical history of perianal dis-
eases (anal fissure, fistula, and abscess) and this factor was 
adjusted in our analysis. A recent Japanese study showed 
no significant difference in the clinical efficacy of IFX and 
ADA in the treatment of perianal fistulas in CD, although 
the number of patients included was very small (31 IFX 
users and 16 ADA users).29 
In conclusion, this large-scale population-based study 
demonstrated that surgery, hospitalization, and corticoste-
roid use did not differ between IFX and ADA users. These 
findings suggest that IFX and ADA have comparable long-
term effectiveness in real-life settings of biologic-naive 
patients with CD. Our study may provide justification for 
allowing patients’ and/or physicians’ preferences to be an 
important factor when choosing between these two biolog-
ics. Our findings can help patients, physicians, and policy-
makers decide how to improve CD treatment.
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